Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.

G, Hess; R, Herbrecht; J, Romaguera; G, Verhoef; M, Crump; C, Gisselbrecht; A, Laurell; F, Offner; A, Strahs; A, Berkenblit; O, Hanushevsky; J, Clancy; B, Hewes; L, Moore; B, Coiffier

doi:10.1200/jco.2008.20.7977

Public

Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.

Shared by NobleBlocks on Jul 6, 2009 • 12:00 AM UTC

Authors:

Hess G

Herbrecht R

Romaguera J

Abstract

<h4>Purpose</h4>Temsirolimus, a specific inhibitor of the mammalian target of rapamycin kinase, has shown clinical activity in mantle cell lymphoma (MCL). We evaluated two dose regimens of temsirolimus in comparison with investigator's choice single-agent therapy in relapsed or refractory disease.<h...

Discussions